Tadalafil Therapy for Pulmonary Arterial Hypertension

By N. Galiè, B. Brundage, H. Ghofrani, R. Oudiz, G. Simonneau, Z. Safdar, S. Shapiro, R. J. White, M. Chan, A. Beardsworth and 2 more. Circulation, 2009

1,037 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/3bea9a1c32d4a7c0fbc3ccdd05452a540ae04e59

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. G. Simonneau

Citations in the corpus

• Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. (2015, neutral): “Disease progression 10 (4) 16 (6) 12 (10) 4 (3)”
• Pulmonary arterial hypertension (2013, methodology): “Galiè and colleagues [237] assessed in the PHIRST trial 405 randomly assigned patients who were either treatment naïve or already receiving bosentan therapy to placebo or one of the several”